
    
      Prospective Open-label Interventional Study Randomized, self-controlled design in which one
      eye receives Dextenza (Group A) intracanalicular insert and the contralateral eye receives
      topical fluorometholone 0.1% BID (Group B) for 2 weeks then once daily for 2 weeks for the
      treatment of ocular rosacea. All patients will be placed on oral doxycycline 100mg BID for
      one month and tapered to a maintenance dose of 100mg once daily for the remainder of the
      study. Patient evaluations will be performed at Screening/Baseline, Insertion Day, Month 1
      and Month 2.
    
  